Brian Czito

Overview:

Listed in Best Doctors in America. Listed in Top Doctors in North Carolina. His research interests include gastrointestinal malignancies, including treatment and integration of novel systemic agents with radiation therapy in the treatment of esophageal, gastric, hepatobiliary, pancreatic, colorectal and anal malignancies; phase I/II clinical trials evaluating novel systemic/targeted agents in conjunction with radiation therapy; investigation and optimization of the treatment of gastrointestinal malignancies, with focus on the above tumor sites.

Positions:

Professor of Radiation Oncology

Radiation Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1996

Medical College of Georgia School of Medicine

Intern

St. Joseph Mercy Health Systems

Resident

Massachusetts General Hospital

Chief Resident

Massachusetts General Hospital

American Board of Radiology (ABR)

American Board of Radiology

Grants:

Phase II Randomized Trial comparing Percutaneous Ablation to Hypofractionaed Image Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocelluar Carcinoma Patients (PROVE-HCC)

Administered By
Radiation Oncology
Role
Principal Investigator
Start Date
End Date

AN ADAPTIVE PHASE I/II DOSE ESCALATION TRIAL OF STEREOTACTIC BODY RADIATION THERAPY IN COMBINATION WITH RADIOMODULATING AGENT GC4419 IN LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA

Administered By
Radiation Oncology
Role
Principal Investigator
Start Date
End Date

Publications:

Multi-institutional analysis of synchronous prostate and rectosigmoid cancers.

Authors
Jacobs, C; Trotter, J; Palta, M; Wu, Y; Willett, C; Lee, WR; Czito, BG
MLA Citation
Jacobs, Corbin, et al. “Multi-institutional analysis of synchronous prostate and rectosigmoid cancers..” Journal of Clinical Oncology, vol. 37, no. 7_suppl, American Society of Clinical Oncology (ASCO), 2019, pp. 33–33. Crossref, doi:10.1200/jco.2019.37.7_suppl.33.
URI
https://scholars.duke.edu/individual/pub1416745
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date
Start Page
33
End Page
33
DOI
10.1200/jco.2019.37.7_suppl.33

Colon Cancer

MLA Citation
Czito, B. G., et al. “Colon Cancer.” Clinical Radiation Oncology, 2015, pp. 977-991.e2. Scopus, doi:10.1016/B978-0-323-24098-7.00050-2.
URI
https://scholars.duke.edu/individual/pub1411897
Source
scopus
Published Date
Start Page
977
End Page
991.e2
DOI
10.1016/B978-0-323-24098-7.00050-2

Intraoperative Irradiation

Authors
Czito, BG; Calvo, FA; Haddock, MG; Palta, M; Willett, CG
MLA Citation
Czito, B. G., et al. “Intraoperative Irradiation.” Clinical Radiation Oncology, 2015, pp. 325-340.e3. Scopus, doi:10.1016/B978-0-323-24098-7.00017-4.
URI
https://scholars.duke.edu/individual/pub1411898
Source
scopus
Published Date
Start Page
325
End Page
340.e3
DOI
10.1016/B978-0-323-24098-7.00017-4

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize major discussion points from the 2014 NCCN Pancreatic Adenocarcinoma Panel meeting. The panel discussion focused mainly on the management of borderline resectable and locally advanced disease. In particular, the panel discussed the definition of borderline resectable disease, role of neoadjuvant therapy in borderline disease, role of chemoradiation in locally advanced disease, and potential role of newer, more active chemotherapy regimens in both settings.
Authors
Tempero, MA; Malafa, MP; Behrman, SW; Benson, AB; Casper, ES; Chiorean, EG; Chung, V; Cohen, SJ; Czito, B; Engebretson, A; Feng, M; Hawkins, WG; Herman, J; Hoffman, JP; Ko, A; Komanduri, S; Koong, A; Lowy, AM; Ma, WW; Merchant, NB; Mulvihill, SJ; Muscarella, P; Nakakura, EK; Obando, J; Pitman, MB; Reddy, S; Sasson, AR; Thayer, SP; Weekes, CD; Wolff, RA; Wolpin, BM; Burns, JL; Freedman-Cass, DA
MLA Citation
Tempero, Margaret A., et al. “Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines..” J Natl Compr Canc Netw, vol. 12, no. 8, Aug. 2014, pp. 1083–93. Pubmed, doi:10.6004/jnccn.2014.0106.
URI
https://scholars.duke.edu/individual/pub1135325
PMID
25099441
Source
pubmed
Published In
J Natl Compr Canc Netw
Volume
12
Published Date
Start Page
1083
End Page
1093
DOI
10.6004/jnccn.2014.0106

Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis.

Aim: To compare the clinical efficacy of neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant chemotherapy (nCT) for esophageal cancer. Methods: Randomized controlled trials reporting on the comparison of nCRT and nCT for esophageal cancer were identified. Results: Three eligible randomized controlled trials were identified and included with a total of 375 patients (189 nCRT, 186 nCT). Outcomes showed that compared with nCT group, R0 resection and pathologic complete response (pCR) rates were significantly increased in nCRT group. However, no significant difference was seen in 3- and 5-year progression-free survival or 3- and 5-year overall survival. Conclusion: The addition of radiotherapy to neoadjuvant chemotherapy results in higher R0 resection rate and pCR rate, without significantly impacting survival.
Authors
Jing, S-W; Qin, J-J; Liu, Q; Zhai, C; Wu, Y-J; Cheng, Y-J; Czito, BG; Wang, J
MLA Citation
Jing, Shao-Wu, et al. “Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis..” Future Oncol, vol. 15, no. 20, July 2019, pp. 2413–22. Pubmed, doi:10.2217/fon-2019-0024.
URI
https://scholars.duke.edu/individual/pub1395763
PMID
31269806
Source
pubmed
Published In
Future Oncol
Volume
15
Published Date
Start Page
2413
End Page
2422
DOI
10.2217/fon-2019-0024